{"id":454632,"date":"2021-03-10T08:03:16","date_gmt":"2021-03-10T13:03:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=454632"},"modified":"2021-03-10T08:03:16","modified_gmt":"2021-03-10T13:03:16","slug":"saniona-to-present-at-the-oppenheimer-31st-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/","title":{"rendered":"Saniona to Present at the Oppenheimer 31st Annual Healthcare Conference"},"content":{"rendered":"
\n

\n PRESS RELEASE<\/b>\n <\/p>\n

\n March 10, 2021<\/b>\n <\/p>\n

\n Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that Rami Levin, President and Chief Executive Officer of Saniona, will present at the Oppenheimer 31st<\/sup> Annual Healthcare Conference being held virtually March 16-18, 2021.<\/b>
\n \n <\/p>\n

\n Details are as follows:<\/b>
\n
Oppenheimer 31st<\/sup> Annual Healthcare Conference
Date: March 17, 2021
Time: 9:20 a.m. Eastern Time
Webcast link: https:\/\/wsw.com\/webcast\/oppenheimer9\/sanion.st\/3758689<\/u><\/a><\/p>\n

The event will be made accessible and archived for approximately 90 days on the Saniona website in the Company Presentations section: https:\/\/saniona.com\/investors\/company-presentations\/<\/u><\/a>. <\/p>\n

\n For more information, please contact <\/b>
\n
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.com<\/u><\/a><\/p>\n

\n The information was submitted for publication, through the agency of the contact person set out above, at 14.00 CET on 10 March 2021.<\/i>\n <\/p>\n

\n About Saniona<\/b>
\n
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company\u2019s lead product candidate, Tesomet, is in mid-stage clinical trials for the rare diseases Prader-Willi syndrome and hypothalamic obesity. Saniona also has a broad pipeline derived from its proprietary ion channel discovery platform, with lead candidate SAN711 entering Phase 1 studies for rare neuropathic disorders. Saniona intends to develop and commercialize its rare disease products internally. The company has out-licensed other programs, which may provide future supplemental revenue. Saniona is based in Copenhagen, Denmark and Boston, Mass., U.S. The company\u2019s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at\u00a0www.saniona.com<\/u><\/a>.<\/p>\n

\n Attachment<\/strong>\n <\/p>\n